Germ cell tumours predominantly of the testis ((T)GCTs) are remarkably chemotherapy sensitive. However, a small proportion of patients fail to be cured with cisplatin-based combination chemotherapy. miR-371a-3p is a new liquid biopsy biomarker for (T)GCTs. The aim of this study was to evaluate clinical utility of 0.08, 95% CI 0.01-27.81, P = 0.008) compared to patients with miR-371a-3p positive in both samples (multivariate analyses were non-significant). In total 68% of the patients were S0. This study demonstrates clinical value of plasma miR-371a-3p level in chemotherapy naïve (T)GCT patients starting first line of chemotherapy to predict prognosis.
all malignancies in the age group between 20 and 40 years.
1,2 TGCTs represent a highly curable malignancy. In fact, cisplatin based chemotherapy is the mainstay in the treatment of TGCTs, resulting in about 70%-80% cure of patients with disseminated disease with a multimodality approach. However, between 20% and 30% of patients do not respond or relapse with this treatment protocol. 2, 3 About 20%-25% of patients with relapsed TGCTs may be cured with various approaches, including salvage chemotherapy based on high-dose chemotherapy with autologous hematopoietic stem-cell rescue or combined with standard cisplatin dose and previously non-utilized drugs. [4] [5] [6] Currently, the clinical management of advanced TGCT disease is based on classical serum protein markers (alpha-fetoprotein [AFP], β-human chorionic gonadotropin [HCG] , and lactate dehydrogenase
[LDH]), and imaging studies. 7, 8 However, only 60% of TGCTs demonstrate elevated serum tumour markers at initial diagnosis. Therefore, in advanced cases, there is a need to identify reliable markers capable of determining chemotherapy effectiveness and patients' outcome.
microRNAs (miRNAs) are involved in important biological processes, both normal as well as pathological, including various types of cancer.
As the discovery of specific embryonic stem cell related miRNAs as relevant oncogenes in TGCTs, 9 various studies evaluated their role in tissues and body fluids of (T)GCT patients. [9] [10] [11] [12] [13] [14] [15] [16] [17] In the largest series to date of 250 TGCT patients, 60 non-TGCT patients at primary diagnosis and 104 male healthy donors, the detection of miR-371a-3p, 373-3p, and 367-3p in sera with the ampTSmiR test was highly informative to diagnose patients with the primary TGCTs.
The data showed an area under the curve (AUC) of 0.96, with a 90% sensitivity and 91% specificity. 14 In an independent study performed with a slightly different protocol and consisting of a series of sera from 166 TGCTs patients and 118 male controls, a positive miR-371a-3p level was found in 88.7% of the patients with the AUC of 0.94, and a 93.4%
specificity. 10 Both studies demonstrated that the detection of miR-371a-3p in serum is far more sensitive and specific than the classical serum markers β-HCG, AFP, and LDH. Furthermore, the miR-371a-3p levels correlate with tumour burden and treatment results. 10 In addition, the four-serum embryonic stem cell related miRNA panel (including miR371a-3p, miR-372-3p, miR-373-3p, and miR-367-3p) also showed a high sensitivity/specificity for diagnosing pediatric (mainly extra-gonadal)
GCTs, based on serum and cerebrospinal fluid analyses. It allowed early detection of relapse of a single mixed tumour and distinguished intracranial malignant GCTs from intracranial non-GCTs at the time of diagnosis. 15 In addition, the ampTSmiR test targeting miR-371a-3p used in our laboratory is more sensitive than the conventional TGCTs protein serum biomarkers for the detection of residual disease and relapse. 13, 14, 18 In conclusion, miR-371a-3p is the most promising miRNA for the detection of (T)GCTs in body fluids to date, performed with a highly sensitive and specific multiplexed pre-amplification quantitative real-time PCR (qRT-PCR) technique. 10, 14 However, in spite of the fact that miR-371a-3p is a promising new specific biomarker for (T)GCTs, data related to its clinical utility are still limited. [9] [10] [11] [12] 18 The aim of this study was to evaluate clinical utility of plasma miR-371a-3p level in chemo-naïve GCTs patients starting systemic chemotherapy. 
| MATERIALS AND METHODS

| Study patients
| Samples collection
Peripheral blood samples were collected from all translational study participants into BD Vacutainer ® EDTA tubes at baseline in the morning on day −1 or 0 of the first cycle of chemotherapy (n = 180) and before the second cycle of chemotherapy (n = 101). Patients' blood samples (5 mL) were centrifuged at 2300 g for 10 minutes to separate the plasma and blood cells. Collected plasma samples were afterwards filtered through a 0.2 μm filter to remove larger particles.
Plasma aliquots were stored at −80°C until further analysis. In total, 281 plasma samples of 180 patients were analysed (Table 1) . Median age of patients was 30 years (range 16-67 years).
The miRNA levels of (T)GCT patients were compared with plasma levels of 50 male healthy donors, of which also serum was available taken at the same time point. Plasma was collected using
Vacuette K3 EDTA Liquid, 6 ml vials (Greiner Bio-One, Alphen aan den Rijn, the Netherlands).
The median age was 54 (range 22-70 years). In our previously reported study, we showed that age did not influence the outcome of the miRNA analysis in sera 14 
| miRNA purification and RT-qPCR
For the ampTSmiR tests specific miRNAs were isolated from 50 μL plasma using target-specific anti-miRNA magnetic beads as described before. 14 In short, cDNA generation and quantification of miRNA levels were performed with a highly sensitive multi- Thermal-cycling conditions: 95°C for 10 minutes, followed by 13 cycles of 95°C for 15 seconds and 60°C for 1 minute. miRNA levels were determined in 1.5 μL of cDNA on a TaqMan 7500
Real-Time PCR system, according to the supplier (Thermo Fisher Scientific).
| Quality control
A non-human miRNA spike-in ath-miR-159a was added in the same fixed amount to the sera (0.2 μL of a 1 nmol/L stock solution) for quality control of RNA isolation and cDNA generation. For calibration of input miRNA levels ath-miR-159a was used. All plasma samples were visually inspected and no hemolytic samples were present that could lead to false interpretation of the results. No samples had to be excluded due to poor miRNA recovery, based on recovery of the spike-in ath-mir-159a (variation in Ct generally within ± 2 Cts, n = 301, SD < 1.67). For normalization the mean levels of the endogenous reference miRNA (miR-30b-5p) were used as described before. 14, 15 In each cDNA synthesis experiment, five 10-fold dilution series of purified miRNA of the TCam-2 seminoma cell line was included for quality control and qPCR efficiency and interplate calibration. For negative control, the no template control, elution buffer was added instead of purified miRNA as described previously. 
T A B L E 1 Patients' characteristics
| Evaluation
The target miRNA level per sample was determined according to 2−ΔΔCT method. 15 Threshold for miR-371a-3p was calculated using plasma samples of healthy donors analysed in this study ( Figure S1 ).
A cut-off value of ≥2.0 (Ct = 29.26) of the highest level (Ct = 30.26) observed in the healthy donor group was used to dichotomize the samples in two categories as positive or negative (cut-off for miR371a-3p = 1) as described earlier. 15 Plasma samples of healthy donors (n = 50) contained similar minimal levels of miR-371a-3p as matched sera, and control sera used in a previous study (n = 104) 14 ( Figure S1 ).
| Statistical analysis
Patient data were tabulated. The patients' characteristics were summarized using the mean or median (range) for continuous variables and frequency (percentage) for categorical variables, respectively.
Statistical analysis was performed using non-parametric tests as the distribution of the miR-371a-3p levels was significantly different from the normal distribution (Shapiro-Wilk test). The Mann-Whitney U test was used for the analysis of the association of the miR-371a-3p expression to clinicopathological variables between the two groups of patients, and Kruskal-Wallis test among more than two groups, whereas Fisher's exact test or the χ 2 test were used when miR-371a-3p expression was categorized as positive or negative.
Wilcoxon test was used to compare plasma the miR-371a-3p before the first and second cycle of chemotherapy. Pearson's correlations were used to determine correlation between serum tumour markers and plasma miR-371a-3p. miR-371a-3p plasma levels and S-stage (as defined by IGCCCG criteria; S0 within normal limits; S1, AFP < 1000 ng/mL and/or β-HCG < 5000 mIU/mL and/or LDH < 1.5 U/L upper normal limit; S2, AFP 1000-10 000 ng/mL and/or β-HCG 5000-50 000 mIU/mL and/ or LDH 1.5-10 U/L upper normal limit; S3 AFP > 10 000 ng/mL and/or β-HCG > 50 000 mIU/mL and/or LDH > 10 U/L upper normal limit).
Data processing and statistical analysis were performed using (Table 2 ). These associations were consistent for plasma miR-371a-3p as continuous variable or dichotomized as positive vs negative, except for response to therapy.
Subgroup analysis showed that both associations were triggered mainly by non-seminomas (Tables S1 and S1 ), where plasma miR371a-3p was associated with primary localization of the tumour as well. In S0 stage patients that represented 73 (40.6%) of study population, there were no associations between plasma miR-371a-3p
and disease characteristics (Table S3 ). None of the five patients with stage IA were miR-371a-3p positive, while four out of 27 patients (29.6%) with stage IB were miR-371a-3p positive and two out of 13 (15.4%) of patients with IS stage were miR-371a-3p positive. Overall, six of 45 patients (13.3%) with CSI were miR-371a-3p
positive. Statistically significant indicated bold. TGCTs, testicular germ cell tumours; IGCCCG, International Germ Cell Consensus Classification Group*defined by IGCCCG criteria; S0, within normal limits; S1, AFP < 1000 ng/mL and/or β-HCG < 5000 mIU/mL and/or LDH < 1.5 U/L upper normal limit; S2, AFP 1000-10 000 ng/mL and/or β-HCG 5000-50 000 mIU/mL and/or LDH 1.5-10 U/L upper normal limit; S3, AFP > 10 000 ng/mL and/or β-HCG > 50 000 mIU/mL and/or LDH > 10 U/L upper normal limit; SEM, standard error of the mean. *Cut-off for miR-371a-3p = 6.89, based on optimal separation of healthy donors and primary (T)GCT patients.
The associations between the histological subtypes of the primary (T)GCT and the plasma miR-371a-3p levels are summarized in Table S4 . Within the whole group, there was no association between histology of primary tumour and plasma miR-371a-3p levels. In stage I disease, there were no differences in plasma miR-371a-3p levels based on histology of primary tumour.
Analysis of 101 paired samples (corresponding samples before starting of first cycle and second cycle of chemotherapy) showed that mean plasma level of miR-371a-3p was significantly higher before the first cycle compared to the second cycle of chemotherapy (mean ± SEM = 33.6 ± 8.1 vs. 0.2 ± 0.1, P < 0.00001) (Figure 1 ). Of 53 patients (52.5%) that were positive for pretreatment miR-371a-3p, only two patients (3.8%), remained positive, one with significant (from 99.9 to 1.5) and second with minor decrease (from 3.3 to 2.2)
of plasma miR-371a-3p, while two patients (2.0%), initially miR-371a-3p negative, became positive before the second cycle of chemotherapy ( Figure S2A ,B).
| Association between serum tumour markers and plasma miR-371a-3p levels
There was correlation between miR-371a-3p continuous levels and serum AFP and LDH, and between miR-371a-3p dichotomized and LDH (Table 3 , Figure S3A ). There was a moderate correlation between serum tumour markers defined as S-stage and plasma miR-371a-3p (Table 3 , Figure S3B ) This was consistent both for seminoma patients (correlation coefficient = 0.32, P = 0.02 as continuous variable and 0.46, P = 0.0006 for dichotomized variable) as well as for non-seminoma patients (correlation coefficient = 0.42, P < 0.00001 as continuous variable and 0.48, P < 0.00001 for dichotomized miR-371a-3p).
In the 101 patients with paired samples, plasma miR-371a-3p positivity before the treatment was in 53 (52.5%) of patients, while positivity of serum tumour markers (stage S1-3) was present in 59 (58.4% of patients). After the first cycle of chemotherapy, only four (4.0%) patients were miR-371a-3p positive while in 27 (26.7%) patients, serum tumour markers remained elevated (P = 0.00005).
| Prognostic value of plasma miR-371a-3p
In the median follow-up time of 20.9 months (range 0. In patients with negative pretreatment plasma miR-371a-3p levels, the biomarker was associated with significantly better PFS and OS compared to patients miR-371a-3p positive (hazard ratio 371a-3p levels, the biomarker was associated with better PFS and OS compared to patients miR-371a-3p positive (HR = 0.39, 95% CI 0.14-1.09, P = 0.13 for PFS and HR = 0.34, 95% CI 0.10-1.09, P = 0.14 for OS, respectively).
In multivariate analysis, pretreatment plasma levels of miR-371a-3p was not independently associated with IGCCCG risk group for PFS (P = 0.20) or OS (P = 0.33) in the whole population (Table 4) nor in the non-seminoma subgroup (not shown), while IGCCCG risk group category was associated with patients' outcome irrespective of plasma miR-371a-3p levels.
Plasma miR-371a-3p level before the second cycle of chemotherapy (N = 101) was not prognostic for PFS or OS (HR = (Table 4 , Figure 2A ,B)
T Cut-off for miR-371a-3p = 1, based on optimal separation of healthy donors and primary (T)GCT patients was used to dichotomize the miRNA test ampTSmiR; (B) overall survival according to relative pretreatment miR-371a-3p plasma level in (testicular) germ cell tumour patients (n = 180) (HR = 0.21, 95% CI 0.07-0.67, P = 0.03); (C) progression-free survival according to relative pretreatment miR-371a-3p plasma level in nonseminoma patients (n = 129) (HR = 0.10, 95% CI 0.03-0.33, P = 0.006). Cut-off for miR-371a-3p = 1, based on optimal separation of healthy donors and primary (T)GCT patients was used to dichotomize the microRNA-371a-3p ampTSmiR test; and (D) overall survival according to relative pretreatment miR-371a-3p plasma level in non-seminoma patients (n = 129) (HR = 0.11, 95% CI 0.03-0.41, P = 0.01) with negative miR-371a-3p in both samples (HR = 0.18, 95% CI 0.10-1.34, P = 0.18 for PFS and HR = 0.19, 95% CI 0.10-1.35, P = 0.19 for OS).
| DISCUSSION
In this translational study, we observed a number of associations between several disease characteristics and pretreatment plasma miR-371a-3p, including IGCCCG risk group, number of metastatic sites, presence of lung, retroperitoneal and mediastinal lymph node metastases, S -stage, and favourable response to therapy. Moreover, these associations were consistent for plasma levels of miR371a-3p analysed as continuous or dichotomized variable (except for response to therapy).
Plasma miR-371a-3p levels were not clearly associated with any histological subtype within the group cohort. This could be due to the low number of more differentiated subtypes like teratoma and or choriocarcinoma and yolk sac tumours. In another study, dysgerminomas possess higher tumour expression of miR-371a-3p compared to mixed GCT germ cell tumours that is consistent with our data. 20 When we analysed stage I patients separately, there were no differences in plasma miR-371a-3p levels based on histology of pri- ple, all teratoma patients had elevated serum tumour markers (four patients were S1, one patient S2, and one patient S3) including elevated β-HCG in three of them suggesting other histologic component in addition to teratoma was present in metastatic sites.
In our study, only 51.7% of the present patients with (T)GCT had elevated levels of miRNA before chemotherapy as opposed to rates around 90% reported in previous studies. 10, 14 This is most likely explained by the fact that in this study the measurements were performed just prior to the start of chemotherapy and not at the moment of orchiectomy. The aim of the study was to show the prognostic value of miR-371a-3p in (T)GCTs and not to compare the survival of miR-371a-3p positive (T)GCT patients to a healthy population.
Plasma miR-371a-3p positivity was found in 13.3% of patients with clinical stage I disease after orchiectomy only. Surprisingly, there was no association between plasma miR-371a-3p levels and some prognostic factors associated with poor outcome, like non-pulmonary visceral metastases or extragonadal GCTs suggesting that miR-371a-3p is indeed a marker associated with tumour burden as suggested before, 10 also in line with the finding that this miR is expressed in all histological elements except teratoma, rather than with treatment resistance. Subgroup analysis revealed that this association is mainly triggered by non-seminomatous histology. However numerically, in seminoma similar trends were observed as in non-seminoma.
In our study we observed for the first-time prognostic value of pretreatment plasma levels of miR-371a-3p for PFS and OS in (T)
GCTs. Subgroup analysis suggested limited prognostic value in seminoma patients and patients with negative serum tumour markers, e.g. subgroups for whom, the disease response could be evaluated only with imaging studies. However, extremely good prognosis of these subgroups and low number of events preclude to draw any definitive conclusion about the prognostic value of plasma miR371a-3p in these subgroups. Multivariate analysis did not show prognostic value of plasma miR-371a-3p levels independently of IGCCCG risk category, an observation that is consistent with strong correlation between several IGCCCG risk factors and plasma miR371a-3p level. Sharp decline in positivity of plasma miR-371a-3p
after one cycle of cisplatin-based chemotherapy compared to serum tumour markers suggest rapid clearance of miR-371a-3p, in agreement with a recent study 10 and implies that plasma miR-371a-3p changes could be early, very sensitive predictor of treatment effect in TGCTs.
14,21
Plasma miR-371a-3p before the second cycle of chemotherapy showed no prognostic value in the whole patient population, probably due to rapid normalization of plasma miR-371a-3p after even one cycle of chemotherapy, an observation consistent with a previous study. 10 On the other hand, patients with positive miR-371a-3p
in both samples had inferior outcome compared to continuously negative patients, suggesting that persistence of plasma miR-371a-3p positivity could be an early marker of treatment failure in TGCTs.
However, due to the low number of patients in subgroups, these results should be confirmed in future studies.
Despite several strengths, this study has some limitations as well, including the retrospective nature of the analysis. Even though this is currently the largest study evaluating plasma miR-371a-3p clinical utility in this patient population, low number of events due to very good prognosis of TGCTs preclude from drawing definitive conclusions in some subpopulation of patients. Moreover, due to the low number of events in subgroups for whom the clinical utility of plasma miR-371a-3p could be largest due to negativity of serum tumour markers (S0-stage disease and/or seminoma), we cannot assess the real clinical utility of plasma miR-371a-3p in these subgroups. In the study presented here the levels of miR-371a-3p have been investigated. We reported an AUC of 0.951, with an 89% specificity and 90% sensitivity for miR-371a-3p and an AUC of 0.962 for the combination of the miRs with specificity of 92% and sensitivity of 91%. 14 However, in our most recent studies addition of the extra miRs compared to miR-371a-3p did not improve the outcome. 13, 18 In addition, other studies are based on only using miR-371. 10, 16, 21 In this large translational study we showed for the first time an association between plasma miR-371a-3p level and several disease characteristics including sites of metastases, serum tumour markers, IGCCCG prognostic group or favourable response to chemotherapy measured at the time just prior to the start of chemotherapy.
Moreover, we observed prognostic value of plasma miR-371a-3p in chemotherapy-naïve GCT patients starting first line of chemotherapy as well as prognostic value of plasma miR-371a-3p changes during the treatment suggesting clinical utility of plasma miR-371a-3p in TGCTs.
